ACLX-002 is under clinical development by Arcellx and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACLX-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ACLX-002 is under development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The immune cell therapy consists of antigen receptor complex T cells (ARC-T) that kills the tumor cells. It acts by targeting cells expressing CD123.The drug candidate is being developed based on ARC-SparX platform.
Arcellx is a biopharmaceutical company which develops, manufactures and markets novel and adaptive cell therapies for the treatment of cancer, acute myeloid leukemia, solid tumors and autoimmune diseases. Arcellx is headquartered in Gaithersburg, Maryland, the US.
For a complete picture of ACLX-002’s drug-specific PTSR and LoA scores, buy the report here.